CY1113461T1 - Μη συνεζευγμενο χολικο οξυ μαζι με propyl gallate και/ή βηα για την αυξηση της απορροφησης μακρο-μοριων - Google Patents
Μη συνεζευγμενο χολικο οξυ μαζι με propyl gallate και/ή βηα για την αυξηση της απορροφησης μακρο-μοριωνInfo
- Publication number
- CY1113461T1 CY1113461T1 CY20121101212T CY121101212T CY1113461T1 CY 1113461 T1 CY1113461 T1 CY 1113461T1 CY 20121101212 T CY20121101212 T CY 20121101212T CY 121101212 T CY121101212 T CY 121101212T CY 1113461 T1 CY1113461 T1 CY 1113461T1
- Authority
- CY
- Cyprus
- Prior art keywords
- bile acid
- propyl gallate
- steps
- acid together
- molecular absorption
- Prior art date
Links
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 title abstract 4
- 239000003613 bile acid Substances 0.000 title abstract 2
- 229940075579 propyl gallate Drugs 0.000 title abstract 2
- 235000010388 propyl gallate Nutrition 0.000 title abstract 2
- 239000000473 propyl gallate Substances 0.000 title abstract 2
- 238000010521 absorption reaction Methods 0.000 title 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical class C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 abstract 1
- 239000000654 additive Substances 0.000 abstract 1
- 230000000996 additive effect Effects 0.000 abstract 1
- 229920002521 macromolecule Polymers 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Η εφεύρεση παρέχει μία φαρμακευτική σύνθεση που περιλαμβάνει ένα μίγμα από: (a) μία δραστική μακρό-μοριακή ουσία και (b) ένα μη συνεζευγμένο χολικό οξύ άλας και (c) ένα πρόσθετο που επιλέγεται από propyl gallate, butyl hydroxy anisole (BHA) και ανάλογα και παράγωγα αυτών, ή μίγματα αυτών.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0308734.3A GB0308734D0 (en) | 2003-04-15 | 2003-04-15 | Uptake of macromolecules |
EP04727588A EP1613355B1 (en) | 2003-04-15 | 2004-04-15 | Non-conjugated bile acid together with propyl gallate and/or BHA to enhance the absorption of macromolecules |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1113461T1 true CY1113461T1 (el) | 2016-06-22 |
Family
ID=9956848
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20121101212T CY1113461T1 (el) | 2003-04-15 | 2012-12-12 | Μη συνεζευγμενο χολικο οξυ μαζι με propyl gallate και/ή βηα για την αυξηση της απορροφησης μακρο-μοριων |
Country Status (20)
Country | Link |
---|---|
US (1) | US8314058B2 (el) |
EP (1) | EP1613355B1 (el) |
JP (1) | JP5047611B2 (el) |
KR (1) | KR101135784B1 (el) |
CN (1) | CN100506280C (el) |
AU (1) | AU2004229217B2 (el) |
BR (1) | BRPI0409413B8 (el) |
CA (1) | CA2522146C (el) |
CY (1) | CY1113461T1 (el) |
DK (1) | DK1613355T3 (el) |
ES (1) | ES2394640T3 (el) |
GB (1) | GB0308734D0 (el) |
HK (1) | HK1078277A1 (el) |
NZ (1) | NZ543172A (el) |
PL (1) | PL1613355T3 (el) |
PT (1) | PT1613355E (el) |
RU (1) | RU2349344C2 (el) |
SI (1) | SI1613355T1 (el) |
WO (1) | WO2004091667A1 (el) |
ZA (1) | ZA200508344B (el) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0308734D0 (en) | 2003-04-15 | 2003-05-21 | Axcess Ltd | Uptake of macromolecules |
GB0308732D0 (en) * | 2003-04-15 | 2003-05-21 | Axcess Ltd | Absorption enhancers |
GB0603252D0 (en) * | 2006-02-17 | 2006-03-29 | Axcess Ltd | Dissolution aids for oral peptide delivery |
WO2008132731A2 (en) * | 2007-04-26 | 2008-11-06 | Oramed Pharmaceuticals, Inc | Methods and compositions for rectal administration of insulin |
AU2009283821B2 (en) | 2008-08-18 | 2014-05-29 | Entera Bio Ltd. | Methods and compositions for oral administration of proteins |
GB0817969D0 (en) * | 2008-10-01 | 2008-11-05 | Axcess Ltd | Pharmaceutical composition |
HUE063336T2 (hu) | 2012-03-19 | 2024-01-28 | Cidara Therapeutics Inc | Adagolási rend echinokandin osztályba tartozó vegyületekhez |
CN106074589A (zh) | 2012-10-17 | 2016-11-09 | 甲基化物科学国际有限公司 | 包含s‑腺苷甲硫氨酸及没食子酸酯的组合物 |
WO2019087083A2 (en) | 2017-10-31 | 2019-05-09 | Medimmune, Llc | Oral delivery of glp-1 peptide analogs |
BR112022014529A2 (pt) * | 2020-01-23 | 2022-09-20 | Axcess Uk Ltd | Absorção celular |
CN116916908A (zh) * | 2021-01-22 | 2023-10-20 | 爱克赛斯(英国)有限公司 | 用于保持治疗化合物完整性的edta和egta |
GB2625490A (en) * | 2021-01-27 | 2024-06-19 | D&D Pharmatech Inc | Pharmaceutical composition comprising large physiologically active substance and excipient |
WO2023038450A1 (ko) * | 2021-09-07 | 2023-03-16 | (주)디앤디파마텍 | 거대 생리활성 물질 및 부형제를 포함하는 약학 조성물 |
KR102412437B1 (ko) | 2022-03-10 | 2022-06-23 | 주식회사 보은기계 | 선택적 시공이 가능한 수로시스템 |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB354184A (en) | 1929-04-30 | 1931-07-29 | Pharmagans Pharmaceutisches In | An improved process for the production of hormone preparations |
US3996355A (en) | 1975-01-02 | 1976-12-07 | American Home Products Corporation | Permanent suspension pharmaceutical dosage form |
JPS5257313A (en) | 1975-11-07 | 1977-05-11 | Yamanouchi Pharmaceut Co Ltd | Manufacture of micellar insuline emulsion preparations |
JPS56138168A (en) | 1980-03-31 | 1981-10-28 | Teijin Ltd | Movel active vitamin d3 derivative composition |
IL68769A (en) | 1983-05-23 | 1986-02-28 | Hadassah Med Org | Pharmaceutical compositions containing insulin for oral administration |
JPS61267528A (ja) | 1984-11-26 | 1986-11-27 | Yamanouchi Pharmaceut Co Ltd | 吸収促進剤を含有するカルシトニン経鼻剤 |
IE59934B1 (en) | 1987-06-19 | 1994-05-04 | Elan Corp Plc | Liquid suspension for oral administration |
US4789660A (en) | 1987-09-10 | 1988-12-06 | American Home Products Corporation | Insulin administration using methyl and propyl paraben |
US5756450A (en) | 1987-09-15 | 1998-05-26 | Novartis Corporation | Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms |
US5474783A (en) | 1988-03-04 | 1995-12-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
US5342625A (en) | 1988-09-16 | 1994-08-30 | Sandoz Ltd. | Pharmaceutical compositions comprising cyclosporins |
IT1251685B (it) | 1991-10-11 | 1995-05-19 | Isf Spa | Composizioni farmaceutiche contenenti una calcitonina |
US5206219A (en) * | 1991-11-25 | 1993-04-27 | Applied Analytical Industries, Inc. | Oral compositions of proteinaceous medicaments |
US5849704A (en) | 1991-12-20 | 1998-12-15 | Novo Nordisk A/S | Pharmaceutical formulation |
US5849700A (en) | 1991-12-20 | 1998-12-15 | Novo Nordisk A/S | Pharmaceutical formulation |
JPH05246846A (ja) | 1992-03-03 | 1993-09-24 | Taiyo Kagaku Co Ltd | 蛋白質の消化促進組成物 |
GB9405304D0 (en) * | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
GB9417524D0 (en) * | 1994-08-31 | 1994-10-19 | Cortecs Ltd | Pharmaceutical compositions |
US5653987A (en) * | 1995-05-16 | 1997-08-05 | Modi; Pankaj | Liquid formulations for proteinic pharmaceuticals |
CA2224227A1 (en) | 1995-06-07 | 1996-12-19 | Avmax, Inc. | Use of essential oils to increase bioavailability of oral pharmaceutical compounds |
WO1997021448A1 (en) | 1995-12-13 | 1997-06-19 | Dullatur Limited | A calcitonin preparation |
CA2198966C (en) | 1996-03-04 | 2011-06-21 | Yuji Suzuki | Method for cleaving chimeric protein using processing enzyme |
US5912014A (en) * | 1996-03-15 | 1999-06-15 | Unigene Laboratories, Inc. | Oral salmon calcitonin pharmaceutical products |
GB9613858D0 (en) | 1996-07-02 | 1996-09-04 | Cortecs Ltd | Hydrophobic preparations |
US5912240A (en) | 1997-04-10 | 1999-06-15 | Loria; Roger M. | 5-androstene 3β, 17α diol as an inhibitor of tumor growth |
US5962522A (en) | 1997-09-05 | 1999-10-05 | Avmax, Inc. | Propyl gallate to increase bioavailability of orally administered pharmaceutical compounds |
US6180666B1 (en) | 1997-09-05 | 2001-01-30 | Anmax, Inc. | Use of gallic acid esters to increase bioavailability of orally administered pharmaceutical compounds |
JP2001525371A (ja) | 1997-12-05 | 2001-12-11 | イーライ・リリー・アンド・カンパニー | Glp−1製剤 |
WO2000022909A2 (en) * | 1998-10-19 | 2000-04-27 | Biotech Australia Pty. Limited | Systems for oral delivery |
US6342249B1 (en) | 1998-12-23 | 2002-01-29 | Alza Corporation | Controlled release liquid active agent formulation dosage forms |
ES2194750T3 (es) | 2000-03-31 | 2003-12-01 | Council Scient Ind Res | Compuestos alimenticio altamente nutritivo basado en cereales. |
JP2003532691A (ja) | 2000-05-05 | 2003-11-05 | ノボ ノルディスク アクティーゼルスカブ | 重症疾患神経障害 |
US7056530B1 (en) | 2000-09-18 | 2006-06-06 | Rpg Life Sciences Ltd. | Selfemulsifiable formulation having enhanced bioabsorption and immunosuppression activities |
GB2368792A (en) * | 2000-10-06 | 2002-05-15 | Roger Randal Charles New | Absorption enhancers |
US6770625B2 (en) * | 2001-09-07 | 2004-08-03 | Nobex Corporation | Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith |
US6951655B2 (en) | 2001-10-11 | 2005-10-04 | Imi Biomed, Inc. | Pro-micelle pharmaceutical compositions |
CN1620281A (zh) | 2001-12-19 | 2005-05-25 | 阿尔扎公司 | 用于治疗剂的受控传递的制剂和剂型 |
GB0206792D0 (en) | 2002-03-22 | 2002-05-01 | Leuven K U Res & Dev | Normoglycemia |
GB0308734D0 (en) | 2003-04-15 | 2003-05-21 | Axcess Ltd | Uptake of macromolecules |
GB0308732D0 (en) * | 2003-04-15 | 2003-05-21 | Axcess Ltd | Absorption enhancers |
-
2003
- 2003-04-15 GB GBGB0308734.3A patent/GB0308734D0/en not_active Ceased
-
2004
- 2004-04-15 PL PL04727588T patent/PL1613355T3/pl unknown
- 2004-04-15 CN CNB200480016322XA patent/CN100506280C/zh not_active Expired - Lifetime
- 2004-04-15 JP JP2006506135A patent/JP5047611B2/ja not_active Expired - Lifetime
- 2004-04-15 KR KR1020057019654A patent/KR101135784B1/ko active IP Right Grant
- 2004-04-15 SI SI200431970T patent/SI1613355T1/sl unknown
- 2004-04-15 EP EP04727588A patent/EP1613355B1/en not_active Expired - Lifetime
- 2004-04-15 NZ NZ543172A patent/NZ543172A/xx not_active IP Right Cessation
- 2004-04-15 CA CA2522146A patent/CA2522146C/en not_active Expired - Lifetime
- 2004-04-15 PT PT47275888T patent/PT1613355E/pt unknown
- 2004-04-15 WO PCT/GB2004/001651 patent/WO2004091667A1/en active Search and Examination
- 2004-04-15 BR BRPI0409413A patent/BRPI0409413B8/pt not_active IP Right Cessation
- 2004-04-15 ES ES04727588T patent/ES2394640T3/es not_active Expired - Lifetime
- 2004-04-15 DK DK04727588.8T patent/DK1613355T3/da active
- 2004-04-15 AU AU2004229217A patent/AU2004229217B2/en not_active Expired
- 2004-04-15 US US10/553,169 patent/US8314058B2/en not_active Expired - Lifetime
- 2004-04-15 RU RU2005135428/15A patent/RU2349344C2/ru not_active IP Right Cessation
-
2005
- 2005-10-14 ZA ZA200508344A patent/ZA200508344B/en unknown
-
2006
- 2006-01-20 HK HK06100995.9A patent/HK1078277A1/xx not_active IP Right Cessation
-
2012
- 2012-12-12 CY CY20121101212T patent/CY1113461T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
JP5047611B2 (ja) | 2012-10-10 |
CN100506280C (zh) | 2009-07-01 |
DK1613355T3 (da) | 2013-01-02 |
ZA200508344B (en) | 2007-12-27 |
PT1613355E (pt) | 2012-12-26 |
KR101135784B1 (ko) | 2012-04-16 |
US8314058B2 (en) | 2012-11-20 |
BRPI0409413A (pt) | 2006-04-25 |
ES2394640T3 (es) | 2013-02-04 |
KR20060021293A (ko) | 2006-03-07 |
BRPI0409413B8 (pt) | 2021-05-25 |
RU2349344C2 (ru) | 2009-03-20 |
NZ543172A (en) | 2009-05-31 |
EP1613355B1 (en) | 2012-09-19 |
SI1613355T1 (sl) | 2013-01-31 |
CA2522146A1 (en) | 2005-10-13 |
US20060122097A1 (en) | 2006-06-08 |
AU2004229217A1 (en) | 2004-10-28 |
HK1078277A1 (en) | 2006-03-10 |
PL1613355T3 (pl) | 2013-09-30 |
RU2005135428A (ru) | 2006-06-10 |
AU2004229217B2 (en) | 2010-03-25 |
GB0308734D0 (en) | 2003-05-21 |
EP1613355A1 (en) | 2006-01-11 |
BRPI0409413B1 (pt) | 2017-05-02 |
CA2522146C (en) | 2012-06-12 |
JP2006523663A (ja) | 2006-10-19 |
CN1805759A (zh) | 2006-07-19 |
WO2004091667A1 (en) | 2004-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1113461T1 (el) | Μη συνεζευγμενο χολικο οξυ μαζι με propyl gallate και/ή βηα για την αυξηση της απορροφησης μακρο-μοριων | |
CY1120994T1 (el) | Καινοτομες συνθεσεις διαλυματος που περιεχουν κυτταρικο παραγοντα και χρηση αυτων για τη θεραπεια τραυματων | |
CY1120462T1 (el) | Τοπικες ανθελμινθικες κτηνιατρικες τυποποιησεις | |
CY1110602T1 (el) | Φαρμακευτικες συνθεσεις υπο μορφη γελης ή διαλυματος με βαση τη διυδροτεστοστερονη, μεθοδοι παρασκευης και χρησεις τους | |
WO2006118948A3 (en) | Therapeutic compositions | |
CY1116023T1 (el) | Μορφες φαρμακευτικης δοσολογιας παρατεταμενης απελευθερωσης με περιγραμματα διαλυτοποιησης ελαχιστοποιημενης εξαρτησης απο το ph | |
CY1107294T1 (el) | Τοπικη συνθεση η οποια περιεχει τουλαχιστον μια βιταμινη d ή ενα αναλογο της βιταμινης d και τουλαχιστον ενα κορτικοστεροειδες | |
NI200600290A (es) | Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso | |
CY1105387T1 (el) | Υποκατεστημενα παραγωγα 2-διαλκυλαμινοαλκυλοδιφαινθλιου | |
BRPI0415121A (pt) | material particulado, forma de dosagem sólida, método para fabricar a mesma, e, uso de um material particulado ou de uma forma de dosagem sólida | |
PL410219A1 (pl) | Kompozycja zawierająca koniugat leku obejmujący pochodne kalicheamycyny i przeciwciało, oraz kompozycja farmaceutyczna ją zawierająca | |
CY1106076T1 (el) | Παραγωγα γλυκοπυρανοσυλοξυβενζυλο βενζολιου και ιατρικες συνθεσεις που πepιεχουν τα ιδια | |
CY1116655T1 (el) | Συνθεσεις ξηρης σκονης γλυκοπυρρολικου και στεατικου μαγνησιου | |
CY1113391T1 (el) | Χρηση ενος συστατικου ενισχυσης διαλυτοτητας σε υδατικη συνθεση που περιλαμβανει τρυγικη βριμονιδινη | |
CR6654A (es) | Composiciones farmaceuticas que proporcionan concentraciones potenciadas de farmaco | |
CY1105247T1 (el) | Υποκατεστημενα παραγωγα c- κυκλοεξυλομεθυλαμινης | |
EA200601554A1 (ru) | Замещенные индол-о-глюкозиды | |
EA200800927A1 (ru) | КОМПОЗИЦИЯ ДЛЯ АЭРОЗОЛЬНОЙ ИНГАЛЯЦИИ β-АГОНИСТОВ | |
CY1109010T1 (el) | γ-ΚΡΥΣΤΑΛΛΙΚΗ ΜΟΡΦΗ ΤΗΣ ΥΔΡΟΧΛΩΡΙΚΗΣ ΙΒΑΒΡΑΔΙΝΗΣ, ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΤΗΣ ΚΑΙ ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΣΥΝΘΕΣΕΙΣ ΠΟΥ ΤΗΝ ΠΕΡΙΕΧΟΥΝ | |
HK1113970A1 (en) | Formulations for injection of catecholic butanes, including ndga compounds, into animals | |
UY27329A1 (es) | Champues con alcohol de behenilo | |
CY1105137T1 (el) | Παραγωγα αμινοκυκλοεξυλ αιθερων και χρησεις τους | |
CY1106386T1 (el) | Υποκατεστημενα παραγωγα 3-πυρρολιδιν-ινδολης | |
CY1112950T1 (el) | Νηματωδοκτονες συνθεσεις | |
CY1106682T1 (el) | Ενωση λακταμης |